RT Journal Article
SR Electronic
T1 The HIP trial
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 964
OP 976
VO 69
IS 12
A1 Deal, Chad L.
YR 2002
UL http://www.ccjm.org/content/69/12/964.abstract
AB The Hip Intervention Program (HIP) trial establishes that risedronate (Actonel) prevents hip fracture in elderly women with osteoporosis. However, the drug had no statistically significant effect on hip fracture risk in elderly women in whom bone density status was not known. Patients should be selected for bisphosphonate therapy on the basis of low bone density. A history of vertebral fractures increases the risk for hip fractures.